Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience

Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Vrankar Martina, Stanic Karmen, Jelercic Stasa, Ciric Eva, Vodusek Ana Lina, But-Hadzic Jasna
Formato: article
Lenguaje:EN
Publicado: Sciendo 2021
Materias:
Acceso en línea:https://doaj.org/article/ae2e857754654969af9f34a239d8657f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!